SK Biopharmaceuticals (326030.KS) will present clinical outcomes, real-world evidence (RWE), pharmacokinetic and long-term efficacy data for cenobamate (marketed as Xcopri in the United States), its novel epilepsy treatment.
The company said Monday that its U.S. subsidiary SK Life Science will deliver a total of 10 poster presentations at the 2026 American Academy of Neurology (AAN) Annual Meeting, to be held from May 18 to 22 in Chicago, Illinois.
In addition to releasing key cenobamate data, SK Life Science plans to present findings analyzing the treatment experiences and communication barriers faced by epilepsy patients and their healthcare providers. The company will also unveil new methodological analysis results from the "Hopes, Hesitations, and Hard Truths" survey, which explored communication gaps between epilepsy patients and clinicians in depth.
The survey, conducted in July last year with 500 patients and 450 healthcare providers in the United States, was first disclosed during Epilepsy Awareness Month in November of the same year. Through this presentation, SK Life Science plans to provide detailed analysis of the survey design and respondent groups, along with additional insights reflecting the perspectives of various stakeholders.
"Understanding the communication gap between patients and healthcare providers in epilepsy management is critical to improving the quality of patient care," said Sunita Misra, Chief Medical Officer of SK Life Science. "The 'Hopes, Hesitations, and Hard Truths' survey will help identify communication gaps in the clinical process and provide insights into the treatment experience."